» Articles » PMID: 38402392

Insulin Resistance and Coronary Inflammation in Patients with Coronary Artery Disease: a Cross-sectional Study

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Insulin resistance (IR) is associated with coronary artery disease (CAD) severity. However, its underlying mechanisms are not fully understood. Therefore, our study aimed to explore the relationship between IR and coronary inflammation and investigate the synergistic and mediating effects of coronary inflammation on the association between IR and CAD severity.

Methods: Consecutive patients with CAD who underwent coronary angiography and coronary computed tomography angiography between April 2018 and March 2023 were enrolled. The triglyceride-glucose index (TyG index) and peri-coronary adipose tissue (PCAT) attenuation around the proximal right coronary artery (RCA) were used to evaluate IR and coronary inflammation, respectively. The correlation between the TyG index and PCAT attenuation was analyzed using linear regression models. Logistic regression models were further used for investigating the correlation of the TyG index and PCAT attenuation with CAD severity. A mediation analysis assessed the correlation between IR and CAD severity mediated by coronary inflammation.

Results: A total of 569 participants (mean age, 62 ± 11 years; 67.8% men) were included in the study. PCAT attenuation was positively associated with the TyG index (r = 0.166; P < 0.001). After adjusting for potential confounders, the per standard deviation increment in the TyG index was associated with a 1.791 Hounsfield unit (HU) increase (95% confidence interval [CI], 0.920-2.662 HU; P < 0.001) in the PCAT attenuation. In total, 382 (67.1%) patients had multivessel CAD. The patients in the high-TyG index/high PCAT attenuation group had approximately 3.2 times the odds of multivessel CAD compared with those in the low-TyG index/low PCAT attenuation group (odds ratio, 3.199; 95%CI, 1.826-5.607; P < 0.001). Mediation analysis indicated that PCAT attenuation mediated 31.66% of the correlation between the TyG index and multivessel CAD.

Conclusions: The TyG index positively correlated with PCAT attenuation in patients with CAD. The TyG index and PCAT attenuation showed a synergistic correlation with multivessel CAD. Furthermore, PCAT attenuation partially mediated the relationship between the TyG index and CAD severity. Controlling inflammation in patients with high IR and coronary inflammation may provide additional benefits.

Citing Articles

Low-density lipoprotein cholesterol predicts coronary artery calcification events in patients with type 2 diabetes: a longitudinal study.

Zou Z, Sun Y, Zou L, Zhou Y, Lin X, Zhou J Diabetol Metab Syndr. 2025; 17(1):53.

PMID: 39940021 PMC: 11823151. DOI: 10.1186/s13098-025-01625-8.


The change of inflammatory markers may predict long-term major adverse cardiovascular events in elderly patients with coronary heart disease: a retrospective cohort study.

He L, Chen S, Zhu X, He F Front Med (Lausanne). 2025; 11:1523581.

PMID: 39871846 PMC: 11769943. DOI: 10.3389/fmed.2024.1523581.


Combining computed tomography features of left atrial epicardial and pericoronary adipose tissue with the triglyceride-glucose index to predict the recurrence of atrial fibrillation after radiofrequency catheter ablation: a machine learning study.

Li X, Wang Z, Wang S, Chen W, Li C, Zhang Y Quant Imaging Med Surg. 2024; 14(12):9306-9322.

PMID: 39698730 PMC: 11651957. DOI: 10.21037/qims-24-1393.


C-reactive protein-triglyceride glucose index predicts stroke incidence in a hypertensive population: a national cohort study.

Tang S, Wang H, Li K, Chen Y, Zheng Q, Meng J Diabetol Metab Syndr. 2024; 16(1):277.

PMID: 39574139 PMC: 11580337. DOI: 10.1186/s13098-024-01529-z.


The triglyceride-glucose index is a predictor of major adverse cardiovascular events in patients with coronary artery disease and psoriasis: a retrospective cohort study.

Fu B, Zeng Y, Wang M, Zhao L, Sun L, Wang T Diabetol Metab Syndr. 2024; 16(1):184.

PMID: 39085887 PMC: 11290256. DOI: 10.1186/s13098-024-01423-8.


References
1.
Tong D, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H . Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020; 142(20):1890-1900. DOI: 10.1161/CIRCULATIONAHA.120.050771. View

2.
Imai K, Keele L, Tingley D . A general approach to causal mediation analysis. Psychol Methods. 2010; 15(4):309-34. DOI: 10.1037/a0020761. View

3.
Tardif J, Kouz S, Waters D, Bertrand O, Diaz R, Maggioni A . Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019; 381(26):2497-2505. DOI: 10.1056/NEJMoa1912388. View

4.
. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View

5.
Hill M, Yang Y, Zhang L, Sun Z, Jia G, Parrish A . Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021; 119:154766. DOI: 10.1016/j.metabol.2021.154766. View